Viracta Therapeutics, Inc. Balance Sheet

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Balance Sheets

In millions of USD, except per-share amounts

	Q3 FY2024 As of Sep 30, 2024	Q2 FY2024 As of Jun 30, 2024	Q1 FY2024 As of Mar 31, 2024	Q4 FY2023 As of Dec 31, 2023	Q3 FY2023 As of Sep 30, 2023	Q2 FY2023 As of Jun 30, 2023	Q1 FY2023 As of Mar 31, 2023	Q4 FY2022 As of Dec 31, 2022	Q3 FY2022 As of Sep 30, 2022	Q2 FY2022 As of Jun 30, 2022	Q1 FY2022 As of Mar 31, 2022	Q4 FY2021 As of Dec 31, 2021	Q3 FY2021 As of Sep 30, 2021	Q2 FY2021 As of Jun 30, 2021	Q1 FY2021 As of Mar 31, 2021	Q4 FY2020 As of Dec 31, 2020	Q3 FY2020 As of Sep 30, 2020	Q2 FY2020 As of Jun 30, 2020	Q1 FY2020 As of Mar 31, 2020	Q4 FY2019 As of Dec 31, 2019
Assets
Current Assets:
Cash and cash equivalents
Restricted cash
Marketable securities
Short-term investments
Prepaid expenses and other current assets
Total current assets

Property and equipment, net
Operating lease right-of-use asset
Other assets
Total assets
Liabilities and stockholders' equity
Current Liabilities:
Accounts payable
Accrued clinical expense
Accrued compensation
Other accrued liabilities
Notes payable
Accrued expenses
Operating lease liabilities
Current portion of long-term debt
Current portion of long-term debt, net
Debt, net
Total current liabilities

Other liabilities
Long-term debt, net
Other Long-Term Debt
Operating lease liabilities, less current portion
Preferred stock warrant liability
Total liabilities
Convertible Preferred Stock
Series A-1 Convertible Preferred Stock
Series B Convertible Preferred Stock
Series C Convertible Preferred Stock
Series D Convertible Preferred Stock
Series E Convertible Preferred Stock
Stockholders' equity:
Convertible preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued and outstanding as of September 30, 2024, and 10,248 shares issued and outstanding as of December 31, 2023
Common stock, $0.0001 par value; 400,000,000 shares authorized; 39,744,222 and 39,093,509 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively
Additional paid-in capital
Accumulated other comprehensive income
Accumulated deficit
Stockholders' equity (deficit)
Series A-1 Convertible Preferred Stock
Series B Convertible Preferred Stock
Series C Convertible Preferred Stock
Series D Convertible Preferred Stock
Series E Convertible Preferred Stock
Total stockholders' equity (deficit)

Total liabilities and stockholders' equity

Comments